IMPACTS OF BLOOD GLUCOSE CONTROL WITH NOVEL DIABETIC DRUGS ON MAJOR ADVERSE CARDIOVASCULAR EVENTS: META-REGRESSION ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Until recently, type 2 diabetes (T2D) therapies other than metformin had little obvious favorable effect on cardiovascular (CV) outcomes. With the availability of many novel armaments, their overall effects of blood glucose control on cardiovascular outcome remains unclear. To investigate the